- Anniversary/History
- Membership
- Publications
- Resources
- Education
- Events
- Outreach
- Careers
- About
- For Pain Patients and Professionals
3-Acetylaconitine (AAC) is a natural compound with strong anti-inflammatory and analgesic properties, but the severely narrow safety range limited its clinical application. Two dissolvable microneedle (MN) systems, AAC-ORP-MN and AAC-MN, loaded with AAC liposomes (AAC-Lips) either mixed with or without Ostrea rivularis polysaccharide (ORP) were developed. The size, zeta potential and encapsulation efficiency of AAC-Lips were 112.9 ± 0.5 nm, -31.3 ± 0.5 mV and 95.7 ± 1.2 %. AAC-ORP-MN demonstrated higher mechanical strength and faster initial drug release rate compared to AAC-MN. The results in the spared nerve injury (SNI) model showed that AAC-ORP-MN and AAC-MN both could significantly increase the mechanical pain threshold on the operated side of the rats, and gradually decrease the difference between the equilibrium pain thresholds of both feet, but AAC-ORP-MN showed a faster onset of action. In addition, AAC-ORP-MN significantly reduced inflammatory factors and improved pathological damage in the spinal cord better than AAC-MN, which might be due to the anti-inflammatory activity of ORP. Overall, the above results supported that AAC-ORP-MN showed promise as a clinical option for analgesia, which had anti-inflammatory and analgesic properties, meanwhile it could effectively deliver poorly water-soluble AAC and improve its safety and availability.